Global

News Releases

This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

14 September 2017 CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

Privigen is now approved for US adult chronic inflammatory demyelinating polyneuropathy (CIDP) patients.

> Read More
07 September 2017 CSL Behring Presents New Alpha 1 Antitrypsin Deficiency Treatment Data at Global ERS Congress

CSL Behring presents data and hosts symposium on real life experiences with Alpha-1.

> Read More
06 September 2017 CSL Behring Joins Together With Others Around the World—Sponsoring the 2017 Meeting of the European Society for Immunodeficiencies (ESID)

Immunoglobulins leader, CSL Behring, sponsors ESID meeting and hosts symposium on new developments in secondary antibody deficiency.

> Read More
25 July 2017 HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema

Global biotherapeutics leader CSL Behring announced today that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in the United States.

> Read More
21 July 2017 CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted the Company seven years of orphan-drug exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of hereditary angioedema (HAE) attacks.

> Read More
Page 2 of 7 First | Next | Last

Share
LinkedIn Twitter Facebook Google+